var data={"title":"Fat emulsion: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fat emulsion: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6181?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fat-emulsion-drug-information\" class=\"drug drug_general\">see &quot;Fat emulsion: Drug information&quot;</a> and <a href=\"topic.htm?path=fat-emulsion-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fat emulsion: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708777\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Deaths in preterm infants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Deaths in preterm infants after infusion of intravenous (IV) fat emulsions have been reported. Autopsy findings included intravascular fat accumulation in the lungs. Treatment of premature and low-birth-weight infants with IV fat emulsion must be based on careful benefit-risk assessment. Strict adherence to the recommended total daily dose is mandatory; hourly infusion rate should be as slow as possible. Preterm infants and low birth weight infants and small for gestational age infants have poor clearance of IV fat emulsion and increased free fatty acid plasma levels following fat emulsion infusion; therefore, serious consideration must be given to administration of less than the maximum recommended doses in these patients to decrease the likelihood of IV fat overload. Monitor the infant's ability to eliminate the infused fat from the circulation (such as triglycerides and/or plasma free fatty acid levels). The lipemia must clear between daily infusions.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170060\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Intralipid;</li>\n      <li>Liposyn III [DSC];</li>\n      <li>Nutrilipid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170061\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Intralipid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058686\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Caloric Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Intravenous Nutritional Therapy</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12674621\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral nutrition:</b> Intralipid, Liposyn III, Nutrilipid: <b>Note:</b> Fat emulsion should not exceed 60% of the total daily calories. At the onset of therapy, the patient should be observed for any immediate allergic reactions such as dyspnea, cyanosis, and fever. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates: IV: Initial dose: 1 to 2 g/kg/day, increase by 0.5 to 1 g/kg/day to a maximum of 3 to 3.5 g/kg/day depending upon the needs/nutritional goals; daily dose infused over 24 hours; total infusion time may be incrementally increased (ie, cycled) to a maximum daily infusion over 12 hours (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum, 2010); do not exceed 1 g/kg in 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term neonates: IV: Initial dose: 1 to 2 g/kg/day, increase by 0.5 to 1 g/kg/day to a maximum of 3 g/kg/day depending upon the needs/nutritional goals; daily dose infused over 24 hours; total infusion time may be incrementally increased (ie, cycled) to a maximum daily infusion over 12 hours (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Localized anesthetic toxicity:</b> Full-term neonate: Very limited data available: 20% fat emulsion: IV: 1 <b>mL</b>/kg was reported in a single case report in a 2-day-old neonate undergoing caudal epidural block for a urologic procedure (Lin, 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058681\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fat-emulsion-drug-information\" class=\"drug drug_general\">see &quot;Fat emulsion: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Parenteral nutrition:</b> Intralipid, Liposyn III, Nutrilipid: <b>Note:</b> Fat emulsion should not exceed 60% of the total daily calories. At the onset of therapy, the patient should be observed for any immediate allergic reactions such as dyspnea, cyanosis, and fever.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: IV: Initial dose: 1 to 2 g/kg/day, increase by 0.5 to 1 g/kg/day to a maximum of 3 g/kg/day depending upon the needs/nutritional goals; daily dose infused over 24 hours; total infusion time may be incrementally increased (ie, cycled) to a maximum daily infusion over 12 hours (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum, 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 10 years: IV: Initial dose: 1 to 2 g/kg/day, increase by 0.5 to 1 g/kg/day to a maximum of 2 to 3 g/kg/day depending upon the needs/nutritional goals; daily dose infused over 24 hours; total infusion time may be incrementally increased (ie, cycled) to a maximum daily infusion over 12 hours (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;11 years and Adolescents: IV: Initial dose: 1 g/kg/day; not to exceed 500 mL 20% fat emulsion on the first day of therapy, increase by 1 g/kg/day to a maximum of 2.5 g/kg/day; daily dose infused over 24 hours; total infusion time may be incrementally increased (ie, cycled) to a maximum daily infusion over 12 hours (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Essential fatty acid deficiency (EFAD), prevention:</b> Intralipid, Liposyn III: Infants, Children, and Adolescents: IV: Administer 8% to 10% of total caloric intake as fat emulsion; infuse 2 to 3 times weekly; may need to increase dose during stress</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Local anesthetic toxicity:</b> Infants, Children, and Adolescents: Limited data available: 20% fat emulsion: IV: 0.8 to 3 <b>mL</b>/kg bolus has been used successfully in several pediatric case reports (1 month to 13 years) (Fuzaylov, 2010; Ludot, 2008; Shah, 2009; Wong, 2010); a single case report in a 6-year-old described use of a continuous IV infusion at 0.25 <b>mL</b>/kg/minute to a total dose of 8 <b>mL</b>/kg following the bolus dose (Wong, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Caloric source:</b> IV: <b>Note:</b> Fat emulsion should not exceed 60% of the total daily calories. Initial dose: 1 to 1.5 g/kg/day (not to exceed 500 mL Intralipid 10% or 20% or 330 mL Intralipid 30% [over 4 to 6 hours] on the first day of therapy); daily dose may be infused over 12 to 24 hours; maximum daily dose: 2.5 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Essential fatty acid deficiency (EFAD), prevention:</b> IV: Administer at least 2% to 4% of total caloric intake as linoleic acid and 0.25% to 0.5% as alpha linolenic acid (Mirtallo, 2004; Mirtallo, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Essential fatty acid deficiency (EFAD), treatment:</b> Intralipid, Liposyn III: IV: Administer 8% to 10% of total caloric intake as fat emulsion; may infuse up to once daily (Riella, 1975). If EFAD occurs with stress, the dosage needed to correct EFAD may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; use with caution. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; use with caution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170047\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intralipid: 20% (100 mL, 250 mL, 500 mL, 1000 mL); 30% (500 mL) [contains egg yolk phospholipids, glycerin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Liposyn III: 30% (500 mL [DSC]) [contains egg phosphatides]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nutrilipid: 20% (250 mL, 500 mL, 1000 mL) [contains egg yolk phospholipids, glycerin]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170033\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22625968\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=fat-emulsion-drug-information\" class=\"drug drug_general\">see &quot;Fat emulsion: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Product oil source for Intralipid and Nutrilipid: soybean</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058690\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> Preparation and administration dependent upon use. All fat emulsion infusions should be filtered whether part of an admixture or infused separately using a 1.2 micron in-line filter only (ISMP 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral nutrition: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intralipid: Prior to opening the overwrap, the integrity indicator should be inspected. If the indicator is black, the overwrap is damaged; do not use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nutrilipid: To avoid air embolism, use a nonvented infusion set or close the air vent on a vented set and use a dedicated line without any connections. Prior to opening the overwrap, the oxygen indicator should be inspected; if the indicator is pink or dark pink, do not use. May be infused concurrently into the same vein as carbohydrate-amino acid solutions by means of a Y-connector located near the infusion site; flow rates of each solution should be controlled separately by infusion pumps. Do not use administration sets and lines that contain di-2-ethylhexyl phthalate (DEHP). See prescribing information for detailed administration information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clinolipid: Prior to opening the overwrap of Clinolipid, check the color of the oxygen indicator and compare to the reference color next to the OK symbol. If the color of the oxygen absorber/indicator does not correspond to the reference color, do not use. After opening the bag, use the contents immediately and do not store for a subsequent infusion. Do not connect flexible bags in series to avoid air embolism due to possible residual gas contained in the primary bag. When preparing total parenteral nutrition admixture, do not use the EXACTAMIX Inlet H938173 with an EXACTAMIX compounder to transfer Clinolipid injection; associated with dislodgement of the administration port membrane into the Clinolipid injection bag. EXACTAMIX Inlet H938174 is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Administer via peripheral line or by central venous infusion. At the onset of therapy, the patient should be observed for any immediate allergic reactions such as dyspnea, cyanosis, and fever. Change tubing after each infusion. The  10% and 20% fat emulsions may be simultaneously infused with amino acid and dextrose mixtures by means of Y-connector located near infusion site into either central or peripheral line or administered in total nutrient mixtures (3-in-1) with amino acids, dextrose, and other nutrients. Fat emulsions of 30% should only be administered in total nutrient mixtures (3-in-1) with amino acids, dextrose, and other nutrients; not intended for direct infusion; must be further diluted to a final concentration not to exceed 20%.  At the bedside, fat emulsion solution should be elevated higher than other parenteral fluids to prevent it running up into other IV lines due to its low specific gravity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates, Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infusion rate: Premature and/or septic neonates and infants may require reduced infusion rates; manufacturers recommend not exceeding 1 g/kg in 4 hours in this population; however, in general for all pediatric patients, lower rates of &le;0.15 to 0.17 g/kg/hour have been recommended by some groups (ASPEN Pediatric Nutrition Support Core Curriculum 2010); in adults, a maximum rate of 0.125 g/kg/hour has been suggested  (Mirtallo 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Product-specific infusion rates (volume):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">10% emulsions: <b>Note:</b> Avoid use of 10% fat emulsion in preterm infants as a greater accumulation of plasma lipids occurs with the greater phospholipid load of the 10% fat emulsion. Liposyn III: Initiate at 0.1 <b>mL</b>/minute for 15 minutes, may increase to &le;100 <b>mL/hour</b> if tolerated</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20% emulsions:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Intralipid: Initiate at &le;0.05 <b>mL</b>/minute for 10 to 15 minutes; if no untoward effects occur, the infusion rate may be increased to 0.5 <b>mL</b>/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Liposyn III: Initiate at 0.1 <b>mL</b>/minute for 15 minutes, may increase to &le;50 <b>mL/hour</b> if tolerated</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Nutrilipid:</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Neonates, Infants, Children, and Adolescents &lt;17 years: Initiate at 0.05 <b>mL</b>/minute for 10 to 15 minutes; if no untoward effects the infusion may be gradually increased to required rate; maximum rate of infusion: Neonates, Infants, and Children &le;10 years: 0.75 <b>mL</b>/kg/<b>hour</b>; Children and Adolescents 11 to 16 years: 0.5 <b>mL</b>/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Adolescents &ge;17 years: Initiate at 0.5 <b>mL</b>/minute for 15 to 30 minutes; if no untoward effects the infusion may be gradually increased; maximum rate of infusion: 0.5 <b>mL</b>/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intralipid, Liposyn III:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">10% emulsions: Initiate at 1 <b>mL</b>/minute for 15 to 30 minutes; if no untoward effects occur, the infusion rate may be increased to 2 <b>mL</b>/minute</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20% emulsions: Initiate at 0.5 mL/minute for 15 to 30 minutes; if no untoward effects occur, the infusion rate may be increased to 1 <b>mL</b>/minute</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nutrilipid: Initiate at 0.5 <b>mL</b>/minute for 15 to 30 minutes; if no untoward effects the infusion may be gradually increased; maximum rate of infusion: 0.5 <b>mL</b>/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Clinolipid: Initiate at 0.5 <b>mL</b>/minute for 15 to 30 minutes; if no untoward effects the infusion may be gradually increased to the required rate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Local anesthetic toxicity:</b> 20% emulsion: Administer initial bolus undiluted over 1 minute; may be administered either peripherally or centrally; bolus may be followed by a continuous infusion depending on clinical scenario. Chest compressions should continue during administration if patient is in cardiac arrest. Continue the infusion for at least 10 minutes after hemodynamic stability is restored. The infusion rate may be increased if hemodynamic instability recurs (ACMT 2010; Neal 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170058\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Do not freeze. If accidentally frozen, discard. Do not store partly used containers; fat emulsion can support the growth of various organisms. Do not use if the emulsion appears to be oiling out. Once the closure is penetrated, the contents should be used as soon as possible; the transfer of contents to suitable TPN admixture containers must be completed within 4 hours of closure penetration. Admixtures prepared using fat emulsion should be used promptly or stored under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for 24 hours or less and used completely within 24 hours after removal from refrigeration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intralipid, Nutrilipid: Store below 25&deg;C (77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058689\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intralipid, Liposyn III: Source of calories and essential fatty acids for patients requiring parenteral nutrition of extended duration (FDA approved in all ages); prevention and treatment of essential fatty acid deficiency (EFAD) (FDA approved in all ages); has also been used for treatment of local anesthetic-induced cardiac arrest unresponsive to conventional resuscitation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nutrilipid: Source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time or when oral or enteral nutrition is not possible, insufficient, or contraindicated (FDA approved in all ages)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clinolipid: Source of calories and essential fatty acids for patients requiring parenteral nutrition of extended duration (FDA approved in adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14599185\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intralipid may be confused with ViperSlide (lubricant used during atherectomy procedures)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170078\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Cholestasis (central lobular), melanosis (brown fat pigmentation in the reticuloendothelial system)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukopenia, splenomegaly, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatomegaly, increased liver enzymes, overloading syndrome (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Back pain, chest pain, cyanosis, diaphoresis, dizziness, drowsiness, dyspnea, flushing, headache, hypercoagulability state, hyperlipidemia, hypersensitivity reaction, increased body temperature, infusion site irritation, nausea, sensation of eye pressure, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170052\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intralipid 20%, 30%: Disturbances in normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if accompanied by hyperlipidemia; pharmacy bulk package is not intended for direct IV administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nutrilipid: Known hypersensitivity to egg or soybean proteins or to any component of the formulation; severe hyperlipidemia (serum triglyceride concentrations above 1,000 mg/dL) or severe disorders of lipid metabolism characterized by hypertriglyceridemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to egg, soya or peanut protein or to any component of the formulation; acute shock; severe hyperlipidemia; conditions characterized by severely disordered fat metabolism (eg, severe hepatic impairment, acute MI, hemophagocytotic syndrome, shock)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170037\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Concerns related to adverse effects</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fat overload syndrome: Although rare, a reduced or limited ability to metabolize lipids accompanied by prolonged plasma clearance resulting in a sudden deterioration in the patient's condition accompanied by fever, anemia, leukopenia, thrombocytopenia, coagulation disorders, hyperlipidemia, liver fatty infiltration (hepatomegaly), deteriorating liver function, and CNS (eg, coma) can occur; usually reversible upon discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Parenteral nutrition: Although the exact etiology is unknown and likely multifactorial, parenteral nutrition associated liver disease (PNALD) has been reported in patients receiving parenteral nutrition for extended periods of time, especially preterm infants, and can present as cholestasis or steatohepatitis, fibrosis and cirrhosis, possibly leading to hepatic failure; cholecystitis and cholelithiasis have also been observed. Consider discontinuation or dose reduction in patients who develop abnormal LFTs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Allergic reactions (eg, tachypnea, dyspnea, hypoxia, bronchospasm, tachycardia, vomiting, headache, sweating) to lipid emulsion may occur; discontinue infusion immediately if signs or symptoms of hypersensitivity or allergic reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Refeeding syndrome: Parenteral nutrition: Refeeding severely undernourished patients with parenteral nutrition may result in the refeeding syndrome (eg, intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic); thiamine deficiency and fluid retention may also develop. Carefully monitor severely undernourished patients and slowly increase their nutrient intakes, while avoiding overfeeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anemia: The use of fat emulsion has been associated with anemia likely due to hemodilution (Zellner 1967). Use with caution in patients with anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fat embolism: Use with caution in patients who may be at danger for fat embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Use with caution in patients with pancreatitis without hyperlipidemia; ensure triglyceride levels remain &lt;400 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution; some formulations may contain aluminum, which may accumulate following prolonged administration in renally impaired patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Toxicity secondary to highly lipid soluble substances: Hemodynamic and other instability: Successful resuscitation following the administration of fat emulsion has been reported in animal studies and several human case reports in which cardiovascular toxicity was unresponsive to conventional resuscitation and antidotal measures. Successful resuscitation following the administration of fat emulsion has been reported in pediatric patients (Fuzaylov 2010; Ludot 2008; Shah 2009; Wong 2010). Additional information is available at http://www.lipidrescue.org. Consider use when toxicity secondary to a highly lipid soluble substance is likely and conventional methods are unsuccessful. Continue CPR throughout treatment with lipid emulsion. Consultation with a medical toxicologist or poison control center is highly recommended.</p>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: <b>[US Boxed Warning]: Deaths in preterm infants following administration of fat emulsion have been reported; autopsy findings included intravascular fat accumulation in the lungs. Premature infants, low birth weight infants, and small for gestational age infants clear intravenous fat emulsion poorly and have increased free fatty acid plasma levels following fat emulsion infusion. Strict adherence to proper infusion rates, dosing, and monitoring are necessary; infusion rate should be as slow as possible; strict monitoring of metabolic tolerance and elimination of infused fat from the circulation must occur.</b> To avoid hyperlipidemia and/or fat deposition, do not exceed recommended daily doses and consider administering less than the maximum recommended doses in preterm and small for gestational age infants. Because free fatty acids displace bilirubin from albumin binding sites, the use of lipid infusions in jaundiced or premature infants should be done with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: The too-rapid administration of fat emulsion can cause fluid and/or fat overloading, resulting in dilution of serum electrolyte concentrations, overhydration, congested states, pulmonary edema, impaired pulmonary diffusion capacity, or metabolic acidosis; hourly infusion rate should be as low as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Three-in-one mixtures: Lipid emulsion in a three-in-one mixture may obscure the presence of a precipitate; follow compounding guidelines, especially for calcium and phosphate additions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170043\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5062137\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Indications for fat emulsion therapy in pregnant women are the same as in nonpregnant women. The ASPEN guidelines for parenteral and enteral nutrition state that intravenous fat emulsion may be used safely in pregnant women to provide calories and prevent essential fatty acid deficiency (ASPEN Guidelines 2002). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015). Lipid emulsion therapy has been used successfully in the resuscitation of a pregnant female with suspected bupivacaine toxicity (Spence 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058685\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for signs and symptoms of infection (including vascular access device complications); fluid and electrolyte status; serum osmolarity; blood glucose; blood counts (including platelets and coagulation parameters); signs and symptoms of essential fatty acid deficiency, refeeding syndrome, and/or hypersensitivity reactions</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Monitor liver and renal function tests periodically. Monitor triglycerides before initiation of lipid therapy and at least weekly during therapy (or until triglycerides are stable and when changes are made in the amount of fat administered) (ASPEN Guidelines, 2002); monitor especially closely in premature infants, septic infants, and patients with pancreatitis or liver disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170036\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fat emulsion is metabolized and utilized as an energy source; provides the essential fatty acids, linoleic acid, and alpha linolenic acid necessary for normal structure and function of cell membranes;  in local anesthetic toxicity, lipid emulsion probably extracts lipophilic local anesthesia from cardiac muscle</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In toxicity secondary to highly lipid soluble substances, exogenous lipids provide an alternative source of binding (Rowlingson 2008), commonly known as the &quot;lipid sink&quot; effect. High lipid partition constant and large volumes of distribution are good predictors of success when using lipid therapy (French 2011). Lipid administration may also affect the heart in a metabolically advantageous way by improving fatty acid transport (Weinberg 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170051\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Fatty acids, phospholipids, and glycerol are metabolized by cells to adenosine triphosphate (ATP), carbon dioxide, and water</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 0.5 to 1 hour</p>\n    <p style=\"text-indent:0em;\">Excretion: Biliary (phospholipids)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058693\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caloric content: 10% emulsion = 1.1 Kcal/mL; 20% emulsion = 2 Kcal/mL; 30% emulsion = 3 Kcal/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus: ~1.5 mMol/100 mL of emulsion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">10% and 20% emulsions are isotonic and may be administered peripherally</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323146\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (Intralipid Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (250 mL): $49.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30% (500 mL): $65.13</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170054\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Intrafat (TW);</li>\n      <li>Intralipid (AE, AU, BG, BH, CH, CN, CY, CZ, DK, EE, EG, ES, FI, HK, HU, ID, IL, IN, IQ, IR, IS, JO, KR, KW, LK, LT, LU, LY, MT, MY, NL, NO, NZ, OM, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SY, TH, TR, UA, YE);</li>\n      <li>Intralipide (FR);</li>\n      <li>Intralipos (KR, MY, TH, TW);</li>\n      <li>Lipofundin-S (MY, TW);</li>\n      <li>Liposyn II (MX, PE);</li>\n      <li>Lipovenos (CL, PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Medical Toxicology (ACMT), &quot;Interim Guidance for the Use of Lipid Resuscitation Therapy,&quot; 2010. Available at http://www.acmt.net/cgi/page.cgi?aid=3384&amp;_id=52&amp;zine=show</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASPEN Board of Directors and the Clinical Guidelines Task Force, &quot;Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,&quot; <i>JPEN J Parenter Enteral Nutr</i>, 2002, 26(1 Suppl):1SA-138SA.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/11841046/pubmed\" target=\"_blank\" id=\"11841046\">11841046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carney LN, Nepa A, Cohen SS, et al, &ldquo;Parenteral and Enteral Nutrition Support: Determining the Best Way to Feed,&rdquo; In: Corkins MR, Balint J, Bobo E, et al, eds, <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>, Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2010, 440-1.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clinolipid (fat emulsion plant based) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colomb V, Jobert-Giraud A, Lacaille F, et al, &quot;Role of Lipid Emulsions in Cholestasis Associated With Long-Term Parenteral Nutrition in Children,&quot; <i>JPEN J Parenter Enteral Nutr</i>, 2000, 24(6):345-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/11071594/pubmed\" target=\"_blank\" id=\"11071594\">11071594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corcoran W, Butterworth J, Weller RS, et al, &quot;Local Anesthetic-Induced Cardiac Toxicity: A Survey of Contemporary Practice Strategies Among Academic Anesthesiology Departments,&quot; <i>Anesth Analg</i>, 2006, 103(5):1322-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/17056977/pubmed\" target=\"_blank\" id=\"17056977\">17056977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department of Health &amp; Human Services, Food and Drug Administration, &quot;Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,&quot; <i>Federal Register</i>, 2000, 65(17):4103-11.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foxall G, McCahon R, Lamb J, et al, &quot;Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,&quot; <i>Anaesthesia</i>, 2007, 62(5):516-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/17448066/pubmed\" target=\"_blank\" id=\"17448066\">17448066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    French D, Smollin C, Ruan W, et al, &ldquo;Partition Constant and Volume of Distribution as Predictors of Clinical Efficacy of Lipid Rescue for Toxicological Emergencies,&rdquo; <i>Clin Toxicol</i>, 2011, 49(9):801-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/21981684/pubmed\" target=\"_blank\" id=\"21981684\">21981684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuzaylov G, Ying B, Tang Y, et al, &quot;Successful Resuscitation After Inadvertent Intravenous Injection of Bupivacaine in an Adolescent,&quot; <i>Paediatr Anaesth</i>, 2010, 20(10):958-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/20849502/pubmed\" target=\"_blank\" id=\"20849502\">20849502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haumont D, Richelle M, Deckelbaum RJ, et al, &ldquo;Effect of Liposomal Content of Lipid Emulsions of Plasma Lipid Concentrations in Low Birth Weight Infants Receiving Parenteral Nutrition,&rdquo; <i>J Pediatr</i>, 1992, 121(5 Pt 1):759-63. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/1432430/pubmed\" target=\"_blank\" id=\"1432430\">1432430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP). IV fat emulsion needs a filter. ISMP Medication Safety Alert. January 14, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intralipid 10% (fat emulsion plant based) [prescribing information]. Uppsala, Sweden: Fresenius Kabi; April 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intralipid 20% (fat emulsion plant based) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intralipid 30% (fat emulsion plant based) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2015. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)</i>, Washington, DC: The National Academies Press, 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin EP and Aronson LA, &quot;Successful Resuscitation of Bupivacaine-Induced Cardiotoxicity in a Neonate,&quot; <i>Paediatr Anaesth</i>, 2010, 20(10):955-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/20849501/pubmed\" target=\"_blank\" id=\"20849501\">20849501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Litz RJ, Popp M, Stehr SN, et al, &quot;Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion,&quot;<i> Anaesthesia</i>, 2006, 61(8):800-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/16867094/pubmed\" target=\"_blank\" id=\"16867094\">16867094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ludot H, Tharin JY, Belouadah M, et al, &quot;Successful Resuscitation After Ropivacaine and Lidocaine-Induced Ventricular Arrhythmia Following Posterior Lumbar Plexus Block in a Child,&quot; <i>Anesth Analg</i>, 2008, 106(5):1572-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/18420879/pubmed\" target=\"_blank\" id=\"18420879\">18420879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo J, Canada T, Johnson D, et al, &ldquo;Safe Practices for Parenteral Nutrition. Task Force for the Revision of Safe Practices for Parenteral Nutrition,&rdquo; <i>JPEN J Parenter Enteral Nutr</i>, 2004, 28(6):S39-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/15568296/pubmed\" target=\"_blank\" id=\"15568296\">15568296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neal JM, Mulroy MF, and Weinberg GL, &quot;American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,&quot; <i>Reg Anesth Pain Med</i>, 2012, 37(1):16-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/22189574/pubmed\" target=\"_blank\" id=\"22189574\">22189574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neuzil J, Darlow BA, Inder TE, et al, &ldquo;Oxidation of Parenteral Lipid Emulsion by Ambient and Phototherapy Lights: Potential Toxicity of Routine Parenteral Feeding,&rdquo; <i>J Pediatr</i>, 1995, 126(5 Pt 1):785-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/7752007/pubmed\" target=\"_blank\" id=\"7752007\">7752007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutrilipid 20% (IV fat emulsion) [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlingson JC, &quot;Lipid Rescue: A Step Forward in Patient Safety? Likely So!&quot; <i>Anesth Analg</i>, 2008, 106(5):1333-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/18420839/pubmed\" target=\"_blank\" id=\"18420839\">18420839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah S, Gopalakrishnan S, Apuya J, et al, &quot;Use of Intralipid in an Infant With Impending Cardiovascular Collapse Due to Local Anesthetic Toxicity,&quot; <i>J Anesth</i>, 2009, 23(3):439-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/19685131/pubmed\" target=\"_blank\" id=\"19685131\">19685131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shin JI, Namgung R, Park MS, et al, &quot;Could Lipid Infusion Be a Risk for Parenteral Nutrition-Associated Cholestasis in Low Birth Weight Neonates?&quot; <i>Eur J Pediatr</i>, 2008, 167(2):197-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/17436017/pubmed\" target=\"_blank\" id=\"17436017\">17436017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinberg GL, Ripper R, Murphy P, et al, &ldquo;Lipid Infusion Accelerates Removal of Bupivacaine and Recovery From Bupivacaine Toxicity in the Isolated Rat Heart,&rdquo; <i>Reg Anesth Pain Med</i>, 2006, 31(4):296-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/16857549/pubmed\" target=\"_blank\" id=\"16857549\">16857549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong GK, Joo DT, and McDonnell C, &quot;Lipid Resuscitation in a Carnitine Deficient Child Following Intravascular Migration of an Epidural Catheter,&quot; <i>Anaesthesia</i>, 2010, 65(2):192-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/19849674/pubmed\" target=\"_blank\" id=\"19849674\">19849674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zellner DC, Iacono JM. &quot;Dilution anemia&quot; associated with multiple infusions of a fat emulsion. <i>Am J Clin Nutr</i>. 1967;20(7):766-776.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-pediatric-drug-information/abstract-text/6036266/pubmed\" target=\"_blank\" id=\"6036266\">6036266</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13296 Version 121.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708777\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F170060\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F170061\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058686\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12674621\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058681\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F170047\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F170033\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F22625968\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058690\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F170058\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058689\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14599185\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F170078\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F170052\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F170037\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F170043\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5062137\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058685\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F170036\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F170051\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1058693\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323146\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F170054\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13296|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fat-emulsion-drug-information\" class=\"drug drug_general\">Fat emulsion: Drug information</a></li><li><a href=\"topic.htm?path=fat-emulsion-patient-drug-information\" class=\"drug drug_patient\">Fat emulsion: Patient drug information</a></li></ul></div></div>","javascript":null}